NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MELT-300 is a combination of midazolam and ketamine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results